# A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

> **NCT07705308** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

## Interventions

- **RADIATION:** Radiation (Very low dose)
- **RADIATION:** Radiation (Standard)

## Key facts

- **NCT ID:** NCT07705308
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2031-05-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705308, "A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*